TEST:

FLT3 ITD MRD Assay

Patients achieving complete remission (CR) or CR with incomplete hematologic recovery (CRi) received ≤4 cycles of high-dose cytarabine + quizartinib (40mg/day) or placebo and/or allo-HCT followed by ~3 years of quizartinib continuation therapy (30-60mg/day) or placebo. Treatment with quizartinib prolonged OS in CR patients compared with placebo, irrespective of allo-HCT in CR1, and in patients undergoing allo-HCT in CR1, irrespective of pre- allo-HCT MRD status.

"Just launched! Invivoscribe’s FLT3 ITD MRD Assay for Acute Myeloid Leukemia (AML)...The FLT3 ITD MRD Assay is a targeted, deep-sequencing assay to identify internal tandem duplications (ITD), the most common mutation of the FLT3 gene. Unlike flow cytometry assays which require fresh sample and are highly subjective, this assay is designed for use with previously isolated DNA for scalable sample batching and an automated Linux-based software, circumventing the need for costly in-house bioinformatics expertise."

Patients achieving complete remission (CR) or CR with incomplete hematologic recovery (CRi) received up to 4 cycles of high-dose cytarabine plus quizartinib (40 mg/d) or placebo and/or allo-HCT followed by up to 3 years of quizartinib continuation therapy (30-60 mg/d) or placebo. Patients on quizartinib had longer OS than patients on placebo, irrespective of allo-HCT in CR1. Patients on quizartinib who underwent allo-HCT in CR1 had longer OS than patients on placebo, irrespective of pre–allo-HCT MRD status.